Valeant Pharmaceuticals expects to find $200 million in savings in 2012

photoTORONTO – Valeant Pharmaceuticals expects to find $200 million of cost savings this year as it works to fully incorporate drug companies acquired in a nearly $3-billion buying spree since merging with Biovail.